Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYNACIRC CR vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
>95%, primarily to albumin and alpha-1 acid glycoprotein.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
2.8 L/kg, indicating extensive tissue distribution.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral (CR): 20-30% due to first-pass metabolism.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
For GFR <30 m L/min, start at 2.5 mg orally once daily; titrate cautiously. No adjustment necessary for GFR >=30 m L/min.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
For Child-Pugh Class A or B: start at 2.5 mg orally once daily. For Child-Pugh Class C: avoid use due to lack of data.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Safety and effectiveness in pediatric patients have not been established.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Initial dose: 2.5 mg orally once daily. Titrate slowly due to increased sensitivity and risk of hypotension.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
None
None
May cause hypotension, especially in volume-depleted patients,Peripheral edema,Hepatic impairment may require dose adjustment,May increase angina or myocardial infarction in patients with obstructive coronary disease upon initiation or dose escalation
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to isradipine or any component,Cardiogenic shock,Acute myocardial infarction
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Grapefruit juice increases isradipine plasma concentrations; avoid concurrent use. High-fat meals may slightly delay absorption but no significant clinical effect.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Isradipine (Dyna Circ CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times the maximum recommended human dose). However, embryotoxicity and fetotoxicity (increased resorptions, reduced fetal weight, delayed ossification) were observed at high doses. There are no adequate and well-controlled studies in pregnant women. Due to the potential risk of fetal harm, use only if the potential benefit justifies the risk. In the first trimester, avoid use if possible. In second and third trimesters, use with caution; may cause maternal hypotension and reduced uteroplacental perfusion.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Isradipine is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.6. Limited data suggest that infant exposure is low. However, due to the potential for adverse effects in the nursing infant (e.g., hypotension, cardiovascular effects), caution should be exercised. Use only if clearly needed and monitor the infant for signs of hypotension or bradycardia.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, increased renal clearance) may reduce isradipine concentrations. Empiric dose adjustment is not routinely recommended, but closer monitoring of blood pressure is advised. If inadequate response occurs, dose may be increased cautiously up to the maximum recommended dose (20 mg/day). No specific pregnancy dose adjustment guidelines exist; individualize therapy based on blood pressure response and tolerability.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
- DYNACIRC CR (isradipine controlled release) is a dihydropyridine calcium channel blocker used for hypertension. - The CR formulation allows once-daily dosing; avoid crushing or chewing tablets. - May cause dose-related peripheral edema, especially in higher doses or in elderly. - Use with caution in patients with aortic stenosis or in those with heart failure due to negative inotropic effects (though less than verapamil). - Grapefruit juice increases bioavailability; consider avoidance or dose adjustment. - Common side effects: headache, dizziness, flushing, and palpitations.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed once daily, preferably in the morning.,Swallow tablet whole; do not crush, chew, or split.,Avoid grapefruit juice while taking this medication.,Do not stop abruptly; may cause rebound hypertension.,Report persistent swelling in ankles/feet, palpitations, or severe dizziness.,May cause dizziness; avoid driving until you know how it affects you.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYNACIRC CR vs ADALAT, answered by our medical review team.
DYNACIRC CR is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYNACIRC CR and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYNACIRC CR is: Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYNACIRC CR and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYNACIRC CR is classified as Category C. Isradipine (DynaCirc CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times . ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.